Pacira Pharma (PCRX) Tops Q1 EPS by 3c ; Offers Guidance

Pacira Pharma (NASDAQ: PCRX) reported Q1 EPS of $0.62, $0.03 better than the analyst estimate of $0.59. Revenue for the quarter came in at $168.92 million versus the consensus estimate of $175.6 million.

GUIDANCE:

Pacira Pharma sees FY2025 revenue of $725-765 million, versus the consensus of $752.9 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Ticketplus files for IPO with shares priced between $13-$15
• Circle board member resigns after nearly 13 years of service